RIGL

AI Memo

Rigel

As of 2026-09-09/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-09 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

VEPPANU launch execution • 2026-12-08

Base target: $53 / p=50% prob

Biggest risk

The VEPPANU launch has not yet been validated by disclosed uptake or reimbursement data, the $70 million upfront payment raises execution and capital-allocation stakes, and R289 remains an early-stage development program. Sparse coverage leaves analyst revisions and market-reaction attribution unavailable.

Invalidation

Break below $38 or thesis failure.

What would change my mind?

Rigel combines record Q2 product sales, profitability, an expanded commercial portfolio through VEPPANU, and potential R289 pipeline value. The reported 2026 outlook provides a concrete execution framework. [#SEC-8K-2026-08-04]

Research note

Recommendation

—

Confidence

medium

As of

2026-09-09

Base target

$53

p=50%

Bull target

$63

p=25%

Bear target

$38

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Execution against 2026 revenue outlook
R289 lower-risk MDS development milestones
Rigel combines record Q2 product sales, profitability, an expanded commercial portfolio through VEPPANU, and potential R289 pipeline value.

BearKey bullets

Analyst revisions, options data, short interest, social sentiment, employee sentiment, and attributed post-earnings market reaction are unavailable.
R289 may face enrollment, dose-selection, efficacy, safety, or timing setbacks.
Rigel must deliver against the updated 2026 revenue outlook of approximately $285-$295 million.

WatchKey bullets

VEPPANU launch execution

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $53 (p=50%)

Target spread vs base: +19% / -28%

Scenario probabilities

Bull Target: $63 (p=25%)Base Target: $53 (p=50%)Bear Target: $38 (p=25%)

Commentary

Primary-source tone is mixed-positive, supported by profitability, updated revenue guidance, VEPPANU launch preparation, and R289 progress. Coverage is sparse, and unavailable analyst revisions, market-reaction attribution, social data, options data, short interest, and employee sentiment limit conviction; this remains a tentative monitoring view. [#SEC-8K-2026-08-04]

As of 2026-09-09 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Execution against 2026 revenue outlook
R289 lower-risk MDS development milestones

Scenarios

Bull Target (Scenario probability)

$63 / p=25% prob

Base Target (Scenario probability)

$53 / p=50% prob

Bear Target (Scenario probability)

$38 / p=25% prob

Analysis 2026-09-09 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-08
VEPPANU launch execution
Rigel completed the exclusive global VEPPANU license, paid a $70 million upfront payment, and expected U.S. commercial availability in mid-August 2026. Early prescribing, reimbursement, channel execution, and contribution to guidance remain unverified and could drive the next material rerating. [#SEC-8K-2026-08-04]
Prob 60.00% • Move 12.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Execution against 2026 revenue outlook
2026-12-31
Rigel reported Q2 2026 revenue of $78.7 million, net product sales of $67.0 million, and net income of $17.3 million, while maintaining an updated 2026 revenue outlook of approximately $285-$295 million. Delivery against that outlook is the key near-term validation point. [#SEC-8K-2026-08-04]
Prob 70% • Move 8% • Priced-in 65%

Long-term Catalysts

Months to a year

R289 lower-risk MDS development milestones
2026-12-31
The Phase 1b dose-expansion study remains on track to complete enrollment, select a recommended Phase 2 dose in the second half of 2026, and provide preliminary data by year-end. This is meaningful pipeline optionality but remains early-stage and clinically risky. [#SEC-8K-2026-08-04]
Prob 50% • Move 20% • Priced-in 35%

Risks

Analyst revisions, options data, short interest, social sentiment, employee sentiment, and attributed post-earnings market reaction are unavailable.
R289 may face enrollment, dose-selection, efficacy, safety, or timing setbacks.
Rigel must deliver against the updated 2026 revenue outlook of approximately $285-$295 million.
The $70 million VEPPANU upfront payment increases execution and capital-allocation risk.
VEPPANU adoption, reimbursement, channel execution, and contribution to guidance remain unverified after the expected mid-August launch.

Peers

Symbol	Summary
AURA	Loose same-sector, similar-market-cap biotechnology comparison; relevant mainly for clinical execution and pipeline optionality rather than Rigel's diversified commercial portfolio.
IMMX	Loose same-sector, similar-market-cap biotechnology comparison; useful as a broad development-risk reference, not a close operating peer.
DRUG	Loose same-sector, similar-market-cap biotechnology comparison; limited operating comparability and mainly useful for small-cap biotech risk context.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-09

Loading AI feed…

Symbol

Summary

AURA

Loose same-sector, similar-market-cap biotechnology comparison; relevant mainly for clinical execution and pipeline optionality rather than Rigel's diversified commercial portfolio.

IMMX

Loose same-sector, similar-market-cap biotechnology comparison; useful as a broad development-risk reference, not a close operating peer.

DRUG

Loose same-sector, similar-market-cap biotechnology comparison; limited operating comparability and mainly useful for small-cap biotech risk context.